3,5-Diamino-2-methylbenzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-Diamino-2-methylbenzoic acid
• 化学式: C₈H₁₀N₂O₂
• mdl: MFCD00047850
• 分子量: 166.18
• InChiKey: RKBQPUFPJRCJKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  89.3
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• ACETYLENE COMPOUND, SALT THEREOF, CONDENSATE THEREOF, AND COMPOSITION THEREOF
  申请人：Fujifilm Corporation

  公开号：EP2202220A1

  公开（公告）日：2010-06-30

  [Problem to be Solved] To provide an acetylene compound having a structure in which a unit having an amino group and a unit having an ethynyl group are bonded via a linking group, the acetylene compound being introducable to a polymer having thermal resistance. [Means for Solving the Problem] An acetylene compound represented by the following Formula (1) and a salt thereof: wherein in Formula (1), X represents a single bond or a divalent linking group; A represents a hydrocarbon group, a heteroaromatic ring or a heteroalicyclic compound; B represents a hydrocarbon group, a heteroaromatic ring, a heteroalicyclic compound or a single bond; R1 represents a hydrogen atom, a hydrocarbon group, a heteroaromatic ring, a heteroalicyclic compound or a silyl group; R4 represents a hydrogen atom or a group that can be a substituent of an amino group; and m, n and a each independently represent an integer of 1 or greater.

  解决的问题是提供一种乙炔化合物，其结构中含有通过连接基团连接的具有氨基团和乙炔基团的单元，该乙炔化合物可引入到具有热阻抗的聚合物中。解决问题的方法是通过以下式（1）表示的乙炔化合物及其盐：其中在式（1）中，X代表单键或二价连接基团；A代表烃基团、杂环芳香环或杂环脂环化合物；B代表烃基团、杂环芳香环、杂环脂环化合物或单键；R1代表氢原子、烃基团、杂环芳香环、杂环脂环化合物或硅基团；R4代表氢原子或可作为氨基团的取代基团；m、n和a分别独立表示大于或等于1的整数。
• Conjugate comprising a neurotensin receptor ligand
  申请人：3B Pharmaceuticals GmbH

  公开号：EP2954933A1

  公开（公告）日：2015-12-16

  The present invention is related to a conjugate comprising a structure of general formula (I)         [TM1] - [AD1] - [LM] - [AD2] - [TM2]     (I), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (II): wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2-adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acid; R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3C8)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK is (C2-C5)alkylidene; R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the following formula (III) wherein ALK' is (C2-C5)alkylidene; R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; and R7 is a bond; or a pharmacologically acceptable salt, solvate or hydrate thereof.

  本发明涉及一种包含一般式（I）结构的结合物，其中TM1是第一靶向基团，第一靶向基团能够结合到第一个靶标，AD1是第一适配基团或者不存在，LM是连接基团或者不存在，AD2是第二适配基团或者不存在，TM2是第二靶向基团，第二靶向基团能够结合到第二个靶标；其中第一靶向基团和/或第二靶向基团是式（II）化合物之一：其中R1选自氢、甲基和环丙基甲基组成的群；AA-COOH是选自2-氨基-2-环戊烷羧酸、环己基甘氨酸和9-氨基-双环[3.3.1]壬烷-9-羧酸组成的氨基酸；R2选自（C1-C6）烷基、（C3-C8）环烷基、（C3-C8）环烷基甲基、卤素、硝基和三氟甲基的群；ALK是（C2-C5）烷基亚基；R3、R4和R5各自独立地选自氢和（C1-C4）烷基，但是在R3、R4和R5中的一个符合以下式（III）：其中ALK'是（C2-C5）烷基亚基；R6选自氢和（C1-C4）烷基；R7是键；或其药理学上可接受的盐、溶剂或水合物。
• Method of making HIV protease inhibitors
  申请人：——

  公开号：US20030216569A1

  公开（公告）日：2003-11-20

  A method of making HIV protease inhibitors of general formula ( 1 ): 1 These HIV compounds inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other antiviral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

  一种制备一般式（1）的HIV蛋白酶抑制剂的方法：这些HIV化合物抑制或阻断HIV蛋白酶酶的生物活性，导致HIV病毒的复制终止。这些化合物以及含有这些化合物和其他光学抗病毒药物作为活性成分的药物组合物，适用于治疗感染HIV病毒的患者或宿主，HIV病毒已知会导致艾滋病。
• [EN] HIV PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTEASE DU VIH
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：WO1995009843A1

  公开（公告）日：1995-04-13

  (EN) HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.(FR) L'invention concerne des inhibiteurs de la protéase du VIH obtenus par synthèse chimique qui inhibent ou bloquent l'activité biologique de la protéase du VIH et stoppent la réplication du virus du VIH. Ces composés, ainsi que les compositions pharmaceutiques contenant ces derniers et éventuellement d'autres agents antiviraux en tant que principes actifs, conviennent au traitement de patients ou d'hôtes infectés par le virus du VIH connu en tant qu'inducteur du SIDA.

  HIV蛋白酶抑制剂是通过化学合成获得的，它们可以抑制或阻止HIV蛋白酶酶的生物活性，导致HIV病毒的复制终止。这些化合物以及包含这些化合物和其他抗病毒剂作为活性成分的制药组合物，适用于治疗感染了HIV病毒的患者或宿主，该病毒已知会导致艾滋病。
• [EN] INTERMEDIATE AND PROCESS FOR MAKING<br/>[FR] INTERMEDIAIRE ET SON PROCEDE DE FABRICATION
  申请人：ELI LILLY AND COMPANY

  公开号：WO1995021164A1

  公开（公告）日：1995-08-10

  (EN) The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating and/or preventing HIV infection and/or AIDS.(FR) La présente invention se rapporte à de nouveaux inhibiteurs de la protéase du VIH, à des formulations pharmaceutiques contenant ces composés et à des procédés conçus pour traiter et/ou prévenir les infections dûes au VIH et/ou le SIDA.

  (中) 本发明提供了新型HIV蛋白酶抑制剂，包含这些化合物的制药配方以及治疗和/或预防HIV感染和/或艾滋病的方法。

表征谱图